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ABSTRACT
In 2015, the UK became the ﬁrst country in the world to
have a comprehensive routine meningococcal vaccine
programme targeting all of the main capsular groups of
N. meningitidis.1 An infant vaccine programme against
meningococcal capsular group B Neisseria meningitidis
(MenB) was launched from 1st September with an aim
to reduce endemic MenB disease in early childhood.
On 1st August 2015, an adolescent programme against
groups A, C, W and Y meningococci (MenACWY) was
rolled out to halt a growing outbreak of capsular group
W disease (MenW) caused by a hypervirulent clone of
N. meningitidis, in addition to maintaining control
against MenC disease provided by the current adolescent
programme.2
INTRODUCTION
Meningococcal disease is the leading infectious
cause of death in early childhood,3 and its control
has been a public health priority for decades. In the
UK, most cases have been caused by MenB and
MenC, with small numbers caused by MenW and
MenY; other capsular groups are rare (ﬁgure 1).
During the 1990s, a rapid rise in cases caused by a
single MenC clone led to the introduction of the
National Health Service (NHS) MenC vaccination
programme in 1999, which successfully controlled
the outbreak and has sustained population protec-
tion against MenC over the past 15 years; it is now
apparent that the success of this programme
depends largely on indirect (herd) protection.4
Meningococci are carried in the nasopharynx of
healthy individuals, particularly adolescents and
young adults, and only cause disease when trans-
mitted to susceptible individuals. MenC vaccines
are made by chemical conjugation of the surface
capsular polysaccharide to a carrier protein—such
as tetanus toxoid or a mutant diphtheria toxoid
(CRM197)—making a highly immunogenic con-
struct. MenC conjugate vaccines provide individual
protection against MenC disease and prevent acqui-
sition of colonisation in the nasopharynx, thereby
interrupting transmission of MenC so that the
wider population is protected. Adjustments to the
MenC programme in recent years have focused on
enhancing immunity among teenagers to prevent
colonisation and thus enhance indirect population
protection as carriage of meningococci is highest
among adolescents.
Since the success of the MenC conjugate vaccin-
ation programme, MenB has been responsible for
almost all cases of invasive meningococcal disease in
the UK, especially in children and young adults. In
England, as in the rest of Europe, MenB cases have
been declining across all age groups: from 1614
cases in the 2000/2001 epidemiological year ( July
2000 to June 2001) to 418 cases in 2014/2015
(ﬁgure 1). This decline is most likely due to natural
secular trends and MenB cases are expected to
increase again at some point in the future (as seen
with MenB and MenC in the mid-1990s), due to,
for example, the introduction of a new MenB strain
into the population. The burden of meningococcal
disease is greatest in young children with half the
cases currently diagnosed in those less than5 years
of age. Infants (<1 year-old) have the highest
number of cases and deaths due to MenB.5 After the
1st year of life, cases decline with age until adoles-
cence where a smaller peak is observed (ﬁgure 2).
Development of vaccines against MenB has been
difﬁcult since its polysaccharide capsule is identical
to saccharides which decorate fetal neural cell
adhesion molecules and are, therefore, poorly
immunogenic self-antigens.6 Previous attempts at
making meningococcal vaccines using subcapsular
antigens have been hampered by poor immunogen-
icity and/or antigenic variability of the antigens,
which has limited progress in the development of
vaccines against highly diverse endemic MenB
strains. Fifteen years ago, however, the ﬁrst menin-
gococcal genome sequence was used to predict
meningococcal surface antigens and to construct
three components of the four-component MenB
vaccine, 4CMenB. The fourth component of the
vaccine is an outer membrane vesicle (OMV) made
by detergent extraction of meningococcal OMVs
from a strain causing an extended outbreak in New
Zealand. This latter component has been used as a
stand-alone vaccine and successfully controlled the
epidemic in New Zealand.7 When combined with
the other three components, 4CMenB is predicted
to cover 73–88% of MenB strains causing invasive
disease in the UK.8 9
After more than a decade of clinical develop-
ment, 4CMenB was licensed by the European
Medicines Agency in early 2013. The potential use
of the vaccine in the UK was considered by the
Department of Health’s Joint Committee on
Vaccination and Immunisation ( JCVI).10 The delib-
erations considered the safety and efﬁcacy of the
vaccine and noted the high case fatality ratio (CFR)
and sequelae rate of the disease, highlighting the
importance of controlling meningococcal disease
for child health in the UK. The cost-effectiveness
analysis for this relatively uncommon disease
showed that the vaccine would only be cost-
effective at a low vaccine price,11 and JCVI
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recommended the vaccine for introduction if such a price could
be met. The negotiations with the manufacturer took a year to
conclude and a programme was announced in June 2015.1
This much anticipated and ground-breaking programme com-
menced in autumn 2015, with a three-dose schedule of
4CMenB to be offered as part of the primary immunisation
schedule at 2 months, 4 months and 12 months of age. When
4CMenB is administered with other routine infant immunisa-
tions, fever occurs in 51–61% of infants.12 Despite previous
advice that paracetamol might interfere with the immune
response to infant vaccines, a recent clinical trial showed that
prophylactic paracetamol signiﬁcantly reduces the rate and
intensity of fever after vaccination with 4CMenB, without
affecting the immune responses to any of the infant vaccines.13
Consequently, parents will be advised to give three doses of
paracetamol when their infants receive 4CMenB as part of the
infant schedule, with the ﬁrst dose given with or as soon as pos-
sible after vaccination. Paediatricians should be aware that, in
clinical trials, some postvaccination fevers resulted in attendance
at medical facilities. A careful history of recent vaccination
should be elicited; fever due to vaccination peaks at around 6 h
and is unlikely to persist beyond 48 h. As with all fevers in
infants, the potential for serious bacterial infection should be
considered, even when temporally related to the vaccine.
Like MenC, 4CMenB was licensed on the basis of immuno-
genicity, although the OMV component has been shown to be
efﬁcacious against matching strains in New Zealand. A speciﬁc
laboratory assay known as Meningococcal Antigen Typing
System was developed as proxy for the existing correlate of pro-
tection, and this was used to predict the proportion of invasive
MenB disease that might be preventable by 4CMenB.8
Consequently, there remains uncertainty about the precise level,
breadth and duration of protection that will be induced by the
new programme. The MenB implementation will be closely
monitored by Public Health England with detailed follow-up of
all laboratory-conﬁrmed cases in children younger than 5 years.
Acute and convalescent sera will be requested to assess immune
responses to meningococcal disease in vaccinated and unvaccin-
ated children. At the same time, meningococcal isolates and
PCR-positive clinical samples will undergo genetic and molecu-
lar testing to determine whether or not they were potentially
preventable by 4CMenB. The UK is, therefore, likely to be the
ﬁrst country to be able to determine vaccine effectiveness in the
ﬁeld. A detailed Public Health England surveillance plan for
England is available online.1 The programme will be reviewed
by JCVI and it is expected that the ﬁrst reliable indications will
become available around 2 years after implementation. The
infant programme is expected to provide direct protection for
Figure 1 Laboratory-conﬁrmed cases
of invasive meningococcal disease in
England by capsular group and
epidemiological year. The blue arrow
denotes the start of the national
immunisation programme against
group C meningococcal (MenC)
disease. Source: Public Health England.
Figure 2 Age distribution of
laboratory-conﬁrmed invasive
meningococcal cases by capsular
group in children and young adults
over the past 10 years (England, 2004/
2005 to 2014/2015).
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vaccinated children but will provide limited indirect (herd) pro-
tection as infants are not thought primarily responsible for car-
riage and transmission of meningococci. Further work is being
undertaken to assess the potential for an adolescent MenB pro-
gramme that, like the MenC immunisation programme, might
induce direct and indirect protection, but requires large-scale
carriage studies and several years to gather the information
required to support such a programme.
Rates of meningococcal disease vary over time as a result of
complex interactions between population immunity and the
meningococcal bacteria, driven by the arrival and eventual dis-
appearance of various clones with differing potential for causing
disease. During the 1990s, a speciﬁc clone, part of the ST-11
complex, and bearing the MenC polysaccharide capsule, caused
a large increase in invasive disease and was associated with a
high CFR. The response to this increase was the accelerated
development and introduction of the MenC vaccine.14 The sub-
sequent control of MenC disease in the UK has acted as a
model for other countries and for other vaccines, including the
recent deployment of conjugate vaccination against group A
meningococci in Africa.15
Until recently in the UK, MenW has been a rare cause of
meningococcal disease, accounting for less than 5% of all cases
across all age groups.5 In the early 2000s, an international out-
break of MenW disease associated with pilgrimage to the Hajj
was terminated by the introduction of mandatory MenACWY
vaccination for all pilgrims.16 Since 2009, however, there has
been a year-on-year increase in the number of MenW cases in
England, from 19 in the 2008/2009 epidemiological year to
176 in 2014/2015, accounting for a quarter of all laboratory-
conﬁrmed meningococcal cases in that year (ﬁgure 3). The
emergent MenW strain belongs to the highly virulent ST-11
clonal complex that was responsible for the UK MenC outbreak
in the 1990s and is genetically identical to MenW strains cur-
rently causing large national outbreaks in South America.2 In
England, MenW cases are being diagnosed across all regions
and all age groups. Most MenW cases are diagnosed in previ-
ously healthy individuals who have not travelled abroad, indicat-
ing that this strain is now established as endemic, and who may
develop severe clinical disease often requiring intensive care
support. Moreover, the clinical presentation has sometimes been
atypical, with septic arthritis and severe respiratory tract infec-
tions (including pneumonia, epiglottitis and supraglottitis) being
over-represented among MenW cases compared with other
meningococcal groups. Several adolescents and young adults
with MenW septicaemia presented primarily with gastrointes-
tinal symptoms and progressed rapidly to death without having
the characteristic non-blanching rash. A consequence of such
atypical presentations is that meningococcal disease is not con-
sidered in the differential diagnosis until a positive culture
becomes available, potentially leading to delays in diagnosis,
offering chemoprophylaxis to close contacts and identifying
clusters and local outbreaks.
The alarming rise in MenW cases probably reﬂects the viru-
lence properties of the ST-11 clonal complex. In South
America, the MenW CFR was 27%.17 In the UK, since its
arrival, MenW CFR has been more than double (12%) that seen
with MenB disease over the same period (<5%), and similar to
that observed with the MenC ST-11 clonal complex outbreak in
the UK in the 1990s.18
Fortunately an effective vaccine for MenW already exists as
part of multicomponent conjugate vaccines that also protect
against group A, C, W and Y meningococci (MenACWY). Like
the MenC conjugates, these vaccines contain the capsular poly-
saccharides of these four meningococcal capsular groups chem-
ically conjugated to tetanus toxoid, CRM197 or diphtheria
toxoid (diphtheria toxoid conjugate only available in the USA).
In February 2015, the Department of Health accepted JCVI’s
advice that the vaccine should be used to control the rapid
increase in the number of MenW cases. From 1st August 2015,
the MenACWY conjugate vaccine will be offered to adolescents
aged 14–18 years because this age group experiences a high
attack rate, and, as with MenC, teenagers and young adults have
the highest carriage rates and are considered to be responsible
for driving transmission.19 The JCVI considered it highly likely
that vaccinating individuals in this age group will result in wide
population protection and eventual control of MenW. Because
the MenACWY conjugate vaccine also protects against MenC
disease, it will replace the MenC conjugate vaccine currently in
the routine adolescent programme from late 2015 to maintain
long-term population control of MenC.
The adolescent MenACWY conjugate vaccine will be intro-
duced as rapidly as possible given the constraints in vaccine
supply. The whole 14–18 year old cohort should be offered the
vaccine during 2015–2017 (table 1). The proposed programme
will:
▸ Prioritise the current school year 13-year-olds (17–18 year
olds) for vaccination through general practice in order to
protect those entering higher education settings such as uni-
versities in the next academic year because 1st year under-
graduate students, especially those living in university halls
of residence, are at signiﬁcantly higher risk of meningococcal
disease than non-students.20 21
▸ Replace MenC with MenACWY vaccination in the existing
time-limited ‘freshers’ programme (ie, for older ﬁrst-time
university entrants who have not already received
MenACWY through school year 13) through general
practice.
▸ Replace MenC with MenACWY vaccination in the routine
adolescent schools programme (school year 9 or 10) from
autumn 2015.
▸ Include a catch-up campaign for current school year 10 stu-
dents through schools from January 2016.
▸ Plan subsequent catch-up campaigns to cover the current
school years 11 and 12 when these students reach year 13.
The introduction of the MenB vaccine for infants may also
provide some protection against MenW, since one of the compo-
nents of 4CMenB vaccine (neisserial adhesion A, NadA) is
found on the surface of the emergent MenW ST-11 clonal
Figure 3 Laboratory-conﬁrmed cases of invasive meningococcal
group W (MenW) disease by age group and epidemiological year in
England.
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complex (unpublished observations). The MenB programme
may, therefore, provide some protection for infants and toddlers
until population control is established through the herd protec-
tion engendered by the adolescent programme.
Currently, the MenC conjugate vaccination programme consists
of a dose at 3 months, 12 months (in a Haemophilus inﬂuenzae
type b/MenC combination) and 13–14 years of age. Once the
MenACWY programme and MenB programmes are fully estab-
lished, it may be possible to drop the infant dose at 3 months
because MenC disease is rare in infants, the adolescent
MenACWY programme will maintain herd protection for the
population and the infant MenB programme may also offer some
protection against other meningococcal capsular groups, includ-
ing MenC. The current programme with these recent changes
can be found here: (https://www.gov.uk/government/uploads/
system/uploads/attachment_data/ﬁle/465880/9406_PHE_
2015_Routine_Childhood_Immunisation_Schedule_12.pdf ).
Because of the established enhanced national surveillance in
place to monitor the MenC programme over the past two
decades, the UK is in a unique position to evaluate the impact of
both new programmes. The implementation of a comprehensive
programme against capsular groups A, B, C, W and Y meningo-
cocci is a huge step forward for child health in the UK. While the
full extent will not be known for several years, these programmes
have the potential to have a major impact on the incidence of
meningococcal disease across the whole population.
More information
Meningococcal B (MenB) vaccination programme
Public Health England. https://www.gov.uk/government/
collections/meningococcal-b-menb-vaccination-programme
(First published 30 June 2015)
Joint Committee on Vaccination and Immunisation, 2014
https://www.gov.uk/government/uploads/system/uploads/
attachment_data/ﬁle/294245/JCVI_Statement_on_MenB.pdf
Contributors All of the authors contributed equally to the development and ﬁnal
review of the manuscript.
Competing interests AJP is Chair of the Department of Health’s Joint Committee
on Vaccination and Immunisation. AJP has previously conducted research on
meningococcal vaccines on behalf of the University of Oxford funded by vaccine
manufacturers but no longer does so, and has not received any personal payments
from manufacturers. RB performs contract research on behalf of Public Health England
for GSK, Novartis, Pﬁzer and Sanoﬁ Pasteur but receives no personal remuneration.
SNL performs contract research on behalf of Public Health England and St. George’s
University of London for vaccine manufacturers but receives no personal remuneration.
JMW is the deputy chief medical ofﬁcer at the Department of Health.
Provenance and peer review Commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Public Health England. Meningococcal B (MenB) vaccination programme. 2015.
https://www.gov.uk/government/publications/menb-vaccination-introduction-from-1-
september-2015
2 Lucidarme J, Hill DMC, Bratcher HB, et al. Genomic resolution of an aggressive,
widespread, diverse and expanding meningococcal serogroup B, C and W lineage.
J Infect 2015;71:544–52.
3 Ladhani S, Pebody RG, Ramsay ME, et al. Continuing impact of infectious diseases
on childhood deaths in England and Wales, 2003–2005. Pediatr Infect Dis J
2010;29:310–13.
4 Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the
meningococcal C conjugate vaccine in England and Wales: effectiveness, validation
of serological correlates of protection, and modeling predictions of the duration of
herd immunity. Clin Vaccine Immunol 2010;17:840–7.
5 Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England
and Wales: implications for the introduction of new vaccines. Vaccine
2012;30:3710–16.
6 Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against
Neisseria meningitidis. N Engl J Med 2010;362:1511–20.
7 Arnold R, Galloway Y, McNicholas A, et al. Effectiveness of a vaccination
programme for an epidemic of meningococcal B in New Zealand. Vaccine
2011;29:7100–6.
8 Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal
multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative
assessment. Lancet Infect Dis 2013;13:416–25.
9 Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a
representative epidemiological meningococcal serogroup B panel conﬁrms
that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31:
4968–74.
10 Joint Committee on Vaccination and Immunisation ( JCVI). JCVI position statement
on use of Bexsero® meningococcal B vaccine in the UK. 2014. https://www.gov.
uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement
Table 1 Summary of the adolescent groups A, C, W and Y meningococci (MenACWY) conjugate vaccination programme in (A) areas that
currently offer the group C meningococcal (MenC) conjugate vaccine to school year 9 and (B) that currently offer the MenC conjugate vaccine to
school year 10 while working towards a transition to a year 9 meningococcal vaccination programme in 2016/2017.
Birth cohort
2014/2015 Academic year
year—age 2014/2015 2015/2016 2016/2017 2017/2018 2018/2019
(a) For areas routinely vaccinating in school year 9
01/09/2003–31/08/2004 Y6—10/11 Y9 ACWY
01/09/2002–31/08/2003 Y7—11/12 Y9 ACWY
01/09/2001–31/08/2002 Y8—12/13 Y9 ACWY
01/09/2000–31/08/2001 Y9—13/14 Y9 MenC Y11 ACWY
01/09/1999–31/08/2000 Y10—14/15 Y11 ACWY
(b) For areas routinely vaccinating in school year 10, working towards a transition to year 9 in 2016/17
01/09/2003–31/08/2004 Y6—10/11 Y9 ACWY
01/09/2002–31/08/2003 Y7—11/12 Y9 ACWY
01/09/2001–31/08/2002 Y8—12/13 Y10 ACWY
01/09/2000–31/08/2001 Y9—13/14 Y10 ACWY
01/09/1999–31/08/2000 Y10—14/15 Y10 MenC Y11 ACWY
94 Ladhani SN, et al. Arch Dis Child 2016;101:91–95. doi:10.1136/archdischild-2015-308928
Review
11 Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of
universal meningitis vaccination (Bexsero) in England: modelling study. BMJ
2014;349:g5725.
12 Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of
recombinant serogroup B meningococcal vaccine administered with or without
routine infant vaccinations according to different immunization schedules:
a randomized controlled trial. JAMA 2012;307:573–82.
13 Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of
a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother
2014;10:1993–2004.
14 Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an
immunisation campaign against meningococcal serogroup C disease in the UK:
a success story. Vaccine 2001;20(Suppl 1):S58–67.
15 Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal
conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and
carriage in Chad: a community study [corrected]. Lancet 2014;383:40–7.
16 Hahné SJ, Gray SJ, Jean-François, et al. W135 meningococcal disease in
England and Wales associated with Hajj 2000 and 2001. Lancet 2002;
359:582–3.
17 Valenzuela MT, Moreno G, Vaquero A, et al. [Emergence of W135
meningococcal serogroup in Chile during 2012]. Rev Med Chil 2013;141:
959–67.
18 Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria
meningitidis capsular group W ST-11 complex associated with severe invasive
disease in England and Wales. Clin Infect Dis 2015;60:578–85.
19 Christensen H, May M, Bowen L, et al. Meningococcal carriage by
age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:
853–61.
20 Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal
disease in college students. JAMA 2001;286:688–93.
21 Nelson SJ, Charlett A, Orr HJ, et al. Risk factors for meningococcal disease in
university halls of residence. Epidemiol Infect 2001;126:211–17.
Ladhani SN, et al. Arch Dis Child 2016;101:91–95. doi:10.1136/archdischild-2015-308928 95
Review
